Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis?

Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis?

Assessing progression of disease or response to treatment remains a major challenge in the clinical management of nontuberculous mycobacterial (NTM) infections of the lungs. Serial assessments of validated measures of treatment response address whether the current therapeutic approach is on track to...

Full description

Bibliographic Details
Main Authors: Christopher Vinnard, Alyssa Mezochow, Hannah Oakland, Ross Klingsberg, John Hansen-Flaschen, Keith Hamilton
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Microbiology
Subjects:
nontuberculous mycobactena
biomarker (development)
response
therapeutics
clinical trial
radiography
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2018.02813/full

Internet

https://www.frontiersin.org/article/10.3389/fmicb.2018.02813/full

Similar Items